Biodexa Pharmaceuticals (BDRX) Short term Debt (2015 - 2025)

Biodexa Pharmaceuticals has disclosed Short term Debt across 11 years of filings, most recently posting $81140.1 for Q4 2025.

• In Q4 2025, Short term Debt fell 89.62% year-over-year to $81140.1; the TTM figure through Dec 2025 stood at $81140.1 (down 89.62% YoY), while the FY2025 annual figure was $80429.1, down 89.67% from the prior year.
• Short term Debt came in at $81140.1 for Q4 2025 at Biodexa Pharmaceuticals, down from $781652.6 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $781652.6 in Q4 2024 to a low of $81140.1 in Q4 2025.
• Average Short term Debt over 5 years is $277237.0, with a median of $201016.6 recorded in 2021.
• Year-over-year, Short term Debt soared 272.65% in 2024 and tumbled 89.62% in 2025.
• Over 5 years, Short term Debt stood at $196809.5 in 2021, then decreased by 4.05% to $188841.5 in 2022, then climbed by 11.07% to $209754.7 in 2023, then soared by 272.65% to $781652.6 in 2024, then sank by 89.62% to $81140.1 in 2025.
• Per Business Quant data, the three most recent Short term Debt figures were $81140.1 in Q4 2025, $781652.6 in Q4 2024, and $209754.7 in Q4 2023.